Phase 4 Irritable Bowel Syndrome Trial, Recruiting NCT06271538 Sponsor: EP Plus Group Sdn Bhd Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Phase 4 Irritable Bowel Syndrome Trial, Recruiting

NCT06271538
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Irritable Bowel Syndrome (IBS) using a standard set of diagnostic guidelines called the Rome IV criteria
  • You are 18 years of age or older (any gender can apply)
  • You have any type of IBS, whether it mainly causes diarrhea, constipation, or a mix of both

Who may not be able to join:

  • You have concerning symptoms such as unexplained weight loss, anemia, symptoms that wake you at night, a lump in your abdomen, or a strong family history of cancer
  • You have taken antibiotics in the past month
  • You have certain medical conditions where taking probiotics would not be safe, such as a severe infection throughout the body (severe sepsis) or if you are pregnant
  • You have been diagnosed with a cancerous growth in your bowel
  • You have had a bowel infection diagnosed within the past month
  • You have had surgery on your abdomen at any point in the past
  • You have a significant mental health condition such as schizophrenia or bipolar disorder with manic episodes
  • You have a known allergy to probiotics
  • You have taken any probiotic supplements within the past month
  • You have previously used the specific probiotic called Skal Pro™ (LP299V™)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Yeong Yeh Lee, MD, PhD, Hospital Universiti Sains Malaysia

Phone: +60122888024

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
EP Plus Group Sdn Bhd
Registry
ClinicalTrials.gov
Start date
17 October 2024
Est. completion
31 March 2026

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

Improving the severity of symptoms in individuals with IBS, assessed by IBS Symptom Severity Scale (IBSSSS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov